Analyst Consensus ?
ConsensusHold25 ratings
Bullish624.0%
Neutral1768.0%
Bearish28.0%
FN2 Earnings Intelligence
Novartis AG (NVS) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| HSBC | Hold | Reduce | Upgrade | Sep 10, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 26, 2026 |
| Barclays | Equal Weight | Underweight | Upgrade | Jan 6, 2026 |
| JP Morgan | Overweight | Neutral | Upgrade | Dec 8, 2025 |
| Goldman Sachs | Sell | Neutral | Downgrade | Sep 12, 2025 |
| UBS | Neutral | Buy | Downgrade | Feb 13, 2025 |
| Erste Group | Hold | Buy | Downgrade | Nov 19, 2024 |
| BMO Capital | Market Perform | Market Perform | Maintain | Oct 30, 2024 |
| B of A Securities | Neutral | Buy | Downgrade | Sep 11, 2024 |
| Jefferies | Hold | Buy | Downgrade | Sep 3, 2024 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | May 9, 2022 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Dec 6, 2021 |
| Bryan Garnier | Neutral | Buy | Downgrade | Dec 3, 2021 |
| Deutsche Bank | Sell | Hold | Downgrade | Sep 20, 2021 |
| Argus Research | Hold | Buy | Downgrade | Mar 10, 2021 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Feb 1, 2021 |
| Guggenheim Securities | Neutral | Buy | Downgrade | Feb 25, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Feb 25, 2020 |
| Citigroup | Buy | Neutral | Upgrade | Sep 11, 2018 |
| Bank of America | Buy | Underperform | Upgrade | Sep 10, 2018 |
| Credit Suisse | Neutral | Underperform | Upgrade | May 25, 2018 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 25, 2018 |
| Natixis | Buy | Neutral | Upgrade | Mar 4, 2015 |
| Hamburger Sparkasse | Hold | Buy | Downgrade | Jan 16, 2013 |
Upside is calculated against the persisted current price $155.07. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Thibault Boutherin | $156 | $140.85 | +0.6% | Oct 6, 2026 |
| HSBC | Analyst unavailable | $136 | $137.48 | -12.3% | Sep 10, 2026 |
| Morgan Stanley | Thibault Boutherin | $170 | $149.7 | +9.6% | Mar 26, 2026 |
| HSBC | Analyst unavailable | $112 | $131.01 | -27.8% | Dec 10, 2025 |
| Morgan Stanley | Analyst unavailable | $143 | $132.28 | -7.8% | Dec 3, 2025 |
| CFRA | Wan Nurhayati | $126 | $123.33 | -18.7% | Oct 29, 2025 |
| BMO Capital | Etzer Darout | $120 | $109.91 | -22.6% | Oct 30, 2024 |
| Goldman Sachs | James Quigley | $121 | $119.38 | -22.0% | Sep 5, 2024 |
| BMO Capital | Etzer Darout | $118 | $106.13 | -23.9% | Jul 19, 2024 |
| CFRA | Wan Nurhayati | $108 | $97.27 | -30.4% | Apr 23, 2024 |
Track every rating change on NVS the moment it posts. Free to start.
Start freeOne email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.